


AusBioInvest 2023 Monday 30 October Park Hyatt Melbourne	
9:00am – 9:20am	Welcome and official opening Welcome to Country The Hon. Tim Pallas , Treasurer, Victorian Government Lorraine Chiroiu , Chief Executive Officer, AusBiotech
9:20am – 9:40am	KEYNOTE
	What biotech investors consider when evaluating a deal: a how-to for non-specialist investors Chair: Lawrence Gozlan , Chief Investment Officer, Scientia Capital Kanishka Pothula , Partner, Nextech Ventures (US) <i>In traditional biotech investing, investors bet on the company's technology or its understanding of disease. But with roughly only 10 per cent of clinical-stage assets making it to market, it's difficult for investors to know which investments will succeed and what will fail. For non-specialist investors wanting to dip their toes into biotech investing, this can be a daunting prospect.</i> <i>North America boasts a large pool of sophisticated life science investors with successful track records in venture creation, commercialisation and M&A. Experienced US investor, Kanishka Pothula, will share insights on how US investors operate, factors US investors consider when making a deal such as evaluation drivers, investment rights, round sizes, and company management, and why this model is successful.</i> <i>Ending with a Q&A, this fireside chat will compare methods used by US and Australian investors, and why it's important to know what drives US investors when seeking seed and expansion capital offshore.</i>

9:40am – 10:35am	COMPANY PRESENTATIONS
	<p>Chair: Stephen Earl, Managing Director, Acuity Capital</p> <p>Dr Michael Baker, Chief Executive Officer & Managing Director, Arovella Therapeutics (ASX:ALA) Dr Paul Gavin, Chief Executive Officer, Avecho Biotechnology (ASX:AVE) Dr Nina Webster, Chief Executive Officer & Managing Director, Dimerix Limited (ASX:DXB) Steven Lydeamore, Chief Executive Officer, Immuron (ASX:IMC) Thian Chew, Executive Chair, Invion (ASX:IVX) Q&A</p>
10:35am – 10:40am	<p>Capital Markets update for listed companies <i>Challenging times and managing through the cycle by using the right tool for the right job at the right time.</i></p> <p>Stephen Earl, Managing Director, Acuity Capital</p>
10:40am – 11:05am	MORNING TEA
11:05am – 12:00pm	COMPANY PRESENTATIONS
	<p>Chair: Sarah Meibusch, Partner, OneVentures</p> <p>Dr Deborah Rathjen, Chief Executive Officer, Carina Biotech Dr Brenton Hamdorf, Chief Executive Officer, Celosia Therapeutics Dr Christian Toouli, Chief Executive Officer & Managing Director, FivepHusion A/Prof Anthony Sasse, Founder & Managing Director, Snoretex Dr Sam Costello, Chief Executive Officer & Co-Founder, BiomeBank Q&A</p>

12:00pm – 12:20pm	KEYNOTE
	<p>ASX market update Chair: Serg Duchini, Non-Executive Director, Enlitic Inc</p> <p>Ajita Tynan, Manager, Listed Company Services ASX Limited</p> <p><i>Providing an overview of ASX as a capital raising platform, outlining the benefits of listing on ASX, including a brief update on ASX IPO and capital raising activity for FY23 and focusing on the performance of the Healthcare sector.</i></p> 
12:20pm – 1:20pm	COMPANY PRESENTATIONS
	<p>Chair: Sarah Meibusch, Partner, OneVentures</p> <p>Zahangir Alam, Chief Executive Officer & Co-Founder, Genofax Brent Barnes, Chief Executive Officer & Managing Director, LBT Innovations (ASX:LBT) Dr Chris Barbe, Chief Executive Officer, EncapSolutions Dr Christos Papadimitriou, Chief Executive Officer, Tessara Therapeutics Dr Isaac Bright, Chief Executive Officer, Imagion Biosystems (ASX:IBX) Vanessa Waddell, Interim Chief Executive Officer, PolyActiva Q&A</p>
1:20pm – 2:10pm	LUNCH

2:10pm – 3:05pm	COMPANY PRESENTATIONS
	<p>Chair: Michael Molinari, Managing Director, IP Group</p> <p>Andrew Maxwell, Chair, Cyban Darryl Davies, Chief Executive Officer, InhaleRx (ASX:IRX) Brian Leedman, Director, Respi (ASX:RSH) Dr Beata Edling, Chief Executive Officer, TruScreen David Hoey, Chief Executive Officer, Vaxxas Q&A</p>
3:05pm – 3:35pm	PANEL DISCUSSION
	<p>How does Australia build the ecosystem to the next stage?</p> <p><i>Australia’s life science ecosystem has seen exponential growth in the past decade, from the number of companies operating in the sector, to individuals employed, patents logged, and therapies commercialised, all of which has a significant and positive impact on Australia’s health and economic wealth. Australia is well-known for its world-class scientific capabilities and research translation, and focus has turned to building a late-stage ecosystem that allows technologies to be wholly developed and manufactured onshore, in turn creating an end-to-end value chain entirely in Australia. Achieving this will require strategic foresight, dedicated capital and innovative thinking from industry and policy makers alike.</i></p> <p><i>Australia boasts the world’s second largest superannuation fund with a reported US\$2568 billion (2022) in assets, sitting just behind the United States with a report US\$2619 (2022) in assets. Several Australian superannuation funds are actively contributing to the sector through their investments into PE and VC firms which invest in Australian biotech.</i></p> <p><i>In this panel discussion, experts will discuss investment approaches to building Australia’s ecosystem, how to unlock the funds already in Australia (such as superannuation capital) to increase access to capital, and why it is critical to attract offshore investors to Australia.</i></p>

	<p>Chair: Dr Amanda Gillon, Senior Partner, Bioscience Managers</p> <p>Panel:</p> <ul style="list-style-type: none"> • Dr Gurkeerat Singh, Associate Vice President, Lilly Ventures – Venture Investing – Asia, Lilly Research Laboratories, Eli Lilly and Company • Dr Megan Baldwin, Chief Executive Officer & Managing Director, Opthea • Neil Stanford, Executive Director, Venture Capital, Breakthrough Victoria
<p>3:35pm – 4:00pm</p>	<p>AFTERNOON TEA</p>
<p>4:00pm – 4:55pm</p>	<p>COMPANY PRESENTATIONS</p>
	<p>Chair: Victoria Durrans, Partner, Bioscience Managers</p> <p>Dr Luke Reid, Chief Executive Officer, Microba Life Sciences Dr Gisela Mautner, Chief Executive Officer & Managing Director, Noxopharm (ASX:NOX) Steven Yatomi-Clarke, Chief Executive Officer & Managing Director, Prescient Therapeutics (ASX: PTX) Penelope Lane, Chief Executive Officer, Esfam Biotech Andrew Shute, Senior Vice President Business Development, EBR Systems (ASX:EBR) Q&A</p>

4:55pm – 5:25pm	KEYNOTE
	<p>Global capital markets Chair: Dr Chris Smith, Partner, Brandon Capital</p> <p>Jennifer Nason, Global Chair, Investment Banking, J.P. Morgan <i>The biotechnology industry relies on steady, patient capital in order to innovate and succeed. With a limited pool of dedicated capital available in Australia, the global capital markets are an attractive place for life science companies to seek investment.</i></p> <p><i>The capital markets Australian biotech companies usually look to have been severely impacted by the post-pandemic macroeconomic turbulence meaning companies must deploy new strategies or look elsewhere to raise capital.</i></p> <p><i>Australia’s most senior woman on Wall Street and Global Chairman of Investment Banking J.P. Morgan, Jennifer Nason, will shed light on the latest shifts and trends in the global capital markets and what that means for the biotech sector both globally and in Australia.</i></p> <p>J.P.Morgan</p>
5:25pm – 5:30pm	WRAP UP & CLOSING REMARKS
	<p>Scott Power, Senior Analyst, Morgans</p>



5:30pm – 6:30pm	Networking Reception Foyer, Park Hyatt Hotel Melbourne <i>Sponsored by:</i> I I I O I TENMILE I O I I I
6:30pm - Late	CEO & Investor Dinner Invitation only – details available on application